Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

2021/05/17 by David S. Khoury, Deborah Cromer, Arnold Reynaldi +7 · 25 citations
Mathematics · Medicine · #COVID-19 Clinical Research Studies #COVID-19 epidemiological studies #SARS-CoV-2 and COVID-19 Research

paper · pdf · doi:10.1038/s41591-021-01377-8

crossref issued 2021/05/17 · crossref published 2021/05/17 · crossref published-online 2021/05/17 · openalex publication_date 2021/05/17 · crossref created 2021/05/17 · crossref published-print 2021/07/01 · crossref deposited 2023/05/20 · openalex created_date 2025/10/10 · crossref indexed 2026/07/28 · openalex updated_date 2026/07/30

Citations

• Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
• An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
• Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
• Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Cited by

• Macrophages direct location-dependent recall of B cell memory to vaccination
• SARS-CoV-2: The Interplay Between Evolution and Host Immunity
• XA-Novo: high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures
• Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice
• Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
• Efficacy of the COVID-19 vaccination in patients with asymptomatic or mild illness during the Omicron epidemic in Guangzhou: a multi-centre retrospective cohort study
• Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults
• Engineering nasally delivered IgM antibodies for respiratory viral infections
• Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection
• An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region
• Role of Vaccination in the Prevention of ECOPD
• Quantifying the waning of humoral immunity
• Population immunity predicts evolutionary trajectories of SARS-CoV-2
• Longitudinal analysis of antibody titers after primary and booster mRNA COVID-19 vaccination can identify individuals at risk for breakthrough infection
• Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis
• Use of the test-negative design to estimate the protective effect of a scalar immune measure: A simulation analysis
• Waning immunity to SARS-CoV-2 following vaccination or infection
• Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors
• A systems biology approach to define SARS-CoV-2 correlates of protection
• In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models
• The impact of Covid-19 vaccination in Aotearoa New Zealand: a modelling study
• The evolutionary epidemiology of pathogens during vaccination campaigns
• Endogenous antigen processing promotes mRNA vaccine CD4 + T cell responses
• A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines
• Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age